News Releases

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic

New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43 rd Annual Global Healthcare Conference at 4:00 p.m.

Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Next Three Years Global Cell Therapy Manufacturing Expert Snehal Patel Appointed Head of Manufacturing Veteran Regulatory Affairs Leader Julie Lepin Appointed Head of Regulatory, Safety, and Quality SEATTLE, June 01, 2022

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D.

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m.

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or

Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of $746.9 million SEATTLE, March 16, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.

SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32 nd Annual Oppenheimer Healthcare Conference at 6:20 a.m.